Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

ProPhase Labs (PRPH) Cash & Equivalents (2016 - 2025)

Historic Cash & Equivalents for ProPhase Labs (PRPH) over the last 16 years, with Q3 2025 value amounting to $405000.0.

  • ProPhase Labs' Cash & Equivalents fell 1916.17% to $405000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $405000.0, marking a year-over-year decrease of 1916.17%. This contributed to the annual value of $678000.0 for FY2024, which is 5786.2% down from last year.
  • According to the latest figures from Q3 2025, ProPhase Labs' Cash & Equivalents is $405000.0, which was down 1916.17% from $169000.0 recorded in Q2 2025.
  • In the past 5 years, ProPhase Labs' Cash & Equivalents registered a high of $32.7 million during Q1 2021, and its lowest value of $88000.0 during Q1 2025.
  • Moreover, its 5-year median value for Cash & Equivalents was $3.8 million (2023), whereas its average is $9.5 million.
  • Its Cash & Equivalents has fluctuated over the past 5 years, first skyrocketed by 459540.89% in 2021, then plummeted by 9735.09% in 2023.
  • Quarter analysis of 5 years shows ProPhase Labs' Cash & Equivalents stood at $8.4 million in 2021, then rose by 8.34% to $9.1 million in 2022, then crashed by 82.34% to $1.6 million in 2023, then tumbled by 57.86% to $678000.0 in 2024, then plummeted by 40.27% to $405000.0 in 2025.
  • Its Cash & Equivalents stands at $405000.0 for Q3 2025, versus $169000.0 for Q2 2025 and $88000.0 for Q1 2025.